Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TScan Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

TWO-YEAR RELAPSE DATA FROM ALLOHA PHASE 1 HEME TRIAL TO BE PRESENTED BY END OF YEAR EXPECTS TO DOSE FIRST SOLID TUMOR PATIENTS WITH MULTIPLEX TCR-T IN THE THIRD QUARTER OF 2025 CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES CONTINUE TO FUND OPERATIONS INTO THE FIRST QUARTER OF 2027 WALTHAM, MASS., AUG. 12, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE.

TSCAN THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WALTHAM, MASS., MAY 28, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE BEING HELD AT THE MARRIOTT MARQUIS IN NEW YORK, NY ON WEDNESDAY, JUNE 4, 2025 AT 4:55 P.M. EASTERN TIME.

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

UPDATES FROM THE PLEXI-T SOLID TUMOR AND ALLOHA HEME PHASE 1 CLINICAL TRIALS ANTICIPATED BY END OF YEAR ON-TRACK TO FILE IND APPLICATION FOR TSC-102-A0301 (CD45; HLA-A*03:01) TO FDA IN THE SECOND HALF OF THE YEAR APPOINTED COMMERCIAL LEADER STEPHEN CAMIOLO AS SENIOR VICE PRESIDENT, MARKET ACCESS CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES CONTINUE TO FUND OPERATIONS INTO THE FIRST QUARTER OF 2027 WALTHAM, MASS., MAY 06, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2025, AND PROVIDED A CORPORATE UPDATE.

TSCAN THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WALTHAM, MASS., APRIL 28, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCEDTHE ACCEPTANCE OF AN ABSTRACT FOR POSTER PRESENTATION AT THE UPCOMING AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT) 28ANNUAL MEETING BEING HELD MAY 13  17 IN NEW ORLEANS, LA AS WELL AS VIRTUALLY.

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY 28TH ANNUAL MEETING

WALTHAM, MASS., MARCH 31, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON MONDAY, APRIL 7, 2025 AT 9:30 A.M. EASTERN TIME.

TSCAN THERAPEUTICS TO PARTICIPATE IN THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

MR. CAMIOLO BRINGS TO TSCAN DEMONSTRATED COMMERCIAL READINESS AND CELL THERAPY LAUNCH EXPERIENCE MR. CAMIOLO BRINGS TO TSCAN DEMONSTRATED COMMERCIAL READINESS AND CELL THERAPY LAUNCH EXPERIENCE

TSCAN THERAPEUTICS APPOINTS COMMERCIAL LEADER STEPHEN CAMIOLO AS SENIOR VICE PRESIDENT, MARKET ACCESS

PRESENTED UPDATED DATA FROM ONGOING ALLOHA PHASE 1 HEME TRIAL AT THE 66 TH ASH ANNUAL MEETING AND EXPOSITION IND APPLICATION CLEARED FOR SEVENTH TCR IN PLEXI-T PHASE 1 SOLID TUMOR PROGRAM; TSC-202-A0201 TARGETING MAGE-A4 ON HLA-A*02:01 CLOSED $30 MILLION REGISTERED DIRECT OFFERING AT 37% PREMIUM WITH LONG-STANDING, SUPPORTIVE SHAREHOLDER CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES CONTINUE TO FUND OPERATIONS INTO THE FIRST QUARTER OF 2027 WALTHAM, MASS., MARCH 05, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS AND FULL YEAR ENDED DECEMBER 31, 2024, AND PROVIDED A BUSINESS UPDATE.

TSCAN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

WALTHAM, MASS., FEB. 27, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT AT THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE BEING HELD AT THE MARRIOTT COPLEY PLACE IN BOSTON, MA ON WEDNESDAY, MARCH 5, 2025 AT 1:10 P.M. EASTERN TIME.

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION AT THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE

WALTHAM, MASS., FEB. 18, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCEDTHAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE H.C. WAINWRIGHT 3RD ANNUAL CELL THERAPY VIRTUAL CONFERENCE ON TUESDAY, FEBRUARY 25, 2025 AT 10:00 A.M. EASTERN TIME.

TSCAN THERAPEUTICS TO PARTICIPATE IN THE H.C. WAINWRIGHT 3RD ANNUAL CELL THERAPY VIRTUAL CONFERENCE

WALTHAM, MASS., DEC. 26, 2024 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH LYNX1 CAPITAL MANAGEMENT LP (LYNX1) AND AN INVESTMENT FUND ADVISED BY LYNX1 FOR THE SALE OF APPROXIMATELY $30 MILLION OF PRE-FUNDED WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 7,500,000 SHARES OF ITS VOTING COMMON STOCK AT A PRICE OF $4.00 PER PRE-FUNDED WARRANT, EACH EXERCISABLE TO PURCHASE ONE SHARE OF VOTING COMMON STOCK AT AN EXERCISE PRICE OF $0.0001 PER SHARE, REPRESENTING A PREMIUM OF 37% TO THE LAST CLOSING PRICE OF TSCAN THERAPEUTICS' COMMON STOCK, AND A 34% PREMIUM OVER THE 10-DAY VOLUME WEIGHTED AVERAGE CLOSING PRICE. THE FINANCING IS EXPECTED TO CLOSE ON OR ABOUTDECEMBER 27, 2024, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.

TSCAN THERAPEUTICS ANNOUNCES $30 MILLION REGISTERED DIRECT OFFERING AT A 37% PREMIUM

NEW NON-DILUTIVE STRUCTURE REPLACES EXISTING CONVERTIBLE FACILITY MATURING IN 2026, AND EXTENDS LOAN MATURITY TO 2029 NEW NON-DILUTIVE STRUCTURE REPLACES EXISTING CONVERTIBLE FACILITY MATURING IN 2026, AND EXTENDS LOAN MATURITY TO 2029

TScan Therapeutics, Inc.

TCRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TScan Therapeutics, Inc.

TCRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TCRX